Where the really big cash comes from is longhaulers. With the results from phase 2 and our ability to further narrow down responders based on biomarker data phase 3 should be a smashing success and we'd be first to market. Around the same time we'd have HIV and U.S. Covid-19 approval. At that point we'd be able to ramp up trials as much as we'd like.

Let's say we partnered with BP for NASH. They'd undoubtedly want worldwide rights for that indication. They'd set the price and undoubtedly it would be much higher than Cytodyn is currently anticipating for leronlimab. Contractually that would certainly lock in the price for all indications. Personally I'd like to see leronlimab be used as widely as possible which means a lower price. If you look at what percentage they'd want to get it wouldn't mean greater revenues.

They may also want a few board members seated. At that point shareholders are at risk for being sold down the river for a fraction of Cytodyn's actual worth. I would rather see Cytodyn fight against the scumminess of BP rather than be owned by it.